Bird & Bird ATMD advised lead investor Hatch Blue in agritech startup Peptobiotics' US$6.2 million Series A funding
Contacts
Bird & Bird ATMD has advised sustainable aquaculture venture capital manager Hatch Blue in its investment from its newly launched US$81 million Blue Revolution Fund in Peptobiotics, a Singapore-based agritech startup in its Series A fundraising.
Founded in 2020, Peptobiotics seeks to replace the use of antibiotics in the aquaculture and later livestock industries, with recombinant antimicrobial peptides. These groundbreaking alternatives to traditional antibiotics promise to combat bacteria without fostering resistance or adverse side effects, paving the way for sustainable protein production.
Hatch Blue led the oversubscribed US$6.2 million funding round. Peptobiotics’ new investors include Seeds Capital, Seventure Partners, GrainCorp Ventures and Farmabase. Existing investors include Trendlines Agrifood Fund, Ponderosa Ventures, and The Yield Lab Asia Pacific, among others.
Peptobiotics will be using the funds to scale its technology, aiming to significantly impact the aquaculture industry by producing commercial volumes of its peptides.
The Bird & Bird team comprised Partner Marcus Chow and Counsel Sabyasachi Chatterjee.
Lead partner Marcus commented, “Collaborating with Hatch Blue on this pivotal Series A funding for Peptobiotics has been an exhilarating journey. This partnership marks a significant milestone for our sustainability and impact investment practice, and we look forward to more collaborations with Hatch Blue to bring about more positive transformation to the aquaculture industries.”
Counsel Sabyasachi added, “It was wonderful working with the Hatch Blue team on this significant transaction, and we are proud to be part of the global movement to encourage more sustainable farming practices.”